Home > Insider Trading > Filing (0001127602-13-032210)

Filing Details

Accession Number:: 0001127602-13-032210
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2013-11-19 16:54:57
Reporting Period:: 2013-11-15

Filing Date:: 2013-11-19
Accepted Time:: 2013-11-19 16:54:57
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1145197	Insulet Corp	PODD	Surgical & Medical Instruments & Apparatus (3841)	043523891

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1395783	Anthony R Diehl	C/O Insulet Corporation 9 Oak Park Drive Bedford MA 01730	Secretary And General Counsel	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2013-11-15	9,976	$17.49	61,347	No	4	M	Direct
Common Stock	Acquisiton	2013-11-15	7,500	$19.14	68,847	No	4	M	Direct
Common Stock	Disposition	2013-11-15	5,000	$35.22	63,847	No	4	S	Direct
Common Stock	Disposition	2013-11-15	7,800	$36.39	56,047	No	4	S	Direct
Common Stock	Disposition	2013-11-15	4,676	$36.86	51,371	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (Right to Buy)	Disposition	2013-11-15	9,976	$0.00	9,976	$17.49
Common Stock	Employee Stock Option (Right to Buy)	Disposition	2013-11-15	7,500	$0.00	7,500	$19.14

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
8,024		2021-03-01	No	4	M	Direct
12,500		2022-04-01	No	4	M	Direct

Footnotes

Includes 6,000 restricted stock units granted on March 1, 2011 which vest on March 1, 2014; 15,000 restricted stock units granted on April 1, 2012 which vest one-third of the total units on April 1, 2014, one-third of the total units on April 1, 2015 and one-third of the total units on April 1, 2016; and 12,500 restricted stock units granted on March 1, 2013 which vest one-quarter of the total units on March 1, 2014, one-quarter of the total units on March 1, 2015, one-quarter of the total units on March 1, 2016 and one-quarter of the total units on March 1, 2017. Vested shares will be delivered to the reporting person as soon as practicable following a vesting date.
Includes an aggregate of 1,249 shares acquired under the Insulet Corporation 2007 Employee Stock Purchase Plan on the following dates: 400 shares acquired on December 31, 2007; and 849 shares acquired on June 30, 2008.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2013.
The price reported represents the weighted average sale price of the shares sold. The shares were sold at varying prices in the range of $34.755 to $35.74. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities Exchange Commission, the Issuer or a security holder of the Issuer, to provide full informaiton regarding the number of shares sold at each separate price.
The price reported represents the weighted average sale price of the shares sold. The shares were sold at varying prices in the range of $35.76 to $36.76. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities Exchange Commission, the Issuer or a security holder of the Issuer, to provide full informaiton regarding the number of shares sold at each separate price.
The price reported represents the weighted average sale price of the shares sold. The shares were sold at varying prices in the range of $36.77 to $37.12. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities Exchange Commission, the Issuer or a security holder of the Issuer, to provide full informaiton regarding the number of shares sold at each separate price.
This option is subject to a four-year vesting period, with 25% of the total award vesting one year after the grant date and the remainder vesting in equal quarterly installments each quarter thereafter for 12 quarters, subject to continued employment.